Research | Michael Pearl, MD

Michael Pearl, MD, FACOG, FACS

Vice-Chair for Research and Faculty Development

Photo of Dr. Michael Pearl

Research Interests
Honors and Grants
Publications and Presentations


Dr. Michael Pearl is Professor and Director of the Division of Gynecologic Oncology in the Department of Obstetrics, Gynecology and Reproductive Medicine, as well as the Gynecologic Oncology Disease Management Team Leader at Stony Brook Medicine. He is Board-Certified in Obstetrics and Gynecology; Gynecologic Oncology; and Hospice and Palliative Medicine; and is a member of the American College of Obstetricians and Gynecologists; American College of Surgeons; the Society of Gynecologic Oncologists; and the American Academy of Hospice and Palliative Medicine. In addition to his clinical activities, Dr. Pearl is the chairman of Stony Brook University’s Committee (B) on Research in Human Subjects. He is the Principal Investigator (PI) at Stony Brook Medicine for NRG Oncology, a National Cancer Institute-funded cooperative research group dedicated to promoting excellence in the quality and integrity of scientific research. In this capacity, he is also responsible as contact PI for eight regional NRG affiliates. Dr. Pearl has authored nearly eighty articles and book chapters in his field and serves as a reviewer for several journals. He has received numerous honors and awards during his career, including several teaching awards from the Department of Obstetrics, Gynecology and Reproductive Medicine and Stony Brook Medicine’s highest award for teaching, the Aesculapius Award. Stony Brook also recognized Dr. Pearl in 2014 with an award for Excellence in Patient Care in a Surgical Discipline. In addition, he has been recognized as a “Top Doctor” for many years by Newsday, Castle Connolly, and the Consumer’s Research Council.  

Return to top ↑ 


Degree(s): MD, University of California School of Medicine, San Francisco, 1986
Residency: Obstetrics and  Gynecology, University of California, San Francisco, 1990
Fellowship: Gynecologic Oncology, University of Michigan, Ann Arbor, 1994

Return to top ↑ 

Research Interests

Ovarian Cancer
Uterine Cancer
General Gynecologic Oncology

Return to top ↑ 


Wen-Tien Chen, PhD, Research Professor of Medical Oncology, Stony Brook Medicine
R. Scott Powers, PhD, Department of Pathology, Stony Brook Medicine

Return to top ↑ 

Honors and Grants (Selection)

J. George Moore Award, Western Association of Gynecologic Oncologists, 1992
ACOG/Elsevier Roy M. Pitkin Award, Obstetrics & Gynecology, 2002
National Faculty Award, Council on Resident Education in Obstetrics & Gynecology, 2003, 2008
"Wave of Hope" AwardLong Island OCEANS (Ovarian Cancer Education Advocacy Network & Support), 2006 
Aesculapius Award, Stony Brook University, School of Medicine, 2010
Excellence in Patient Care in a Surgical Discipline Award, Stony Brook Medicine, 2014

an image is hereSee Dr. Pearl's complete CV at SciENcv

Return to top ↑ 

Publications and Presentations (Selection)

1.Pearl ML, Zhao Q, Yang J, Dong H, Tulley S, Zhang Q, Golightly M, Zucker S, Chen WT. Prognostic analysis of invasive circulating tumor cells (iCTCs) in epithelial ovarian cancer. Gynecol Oncol. 2014 Sep;134(3):581-90.[PubMed]
2.Stevens EE, Yu S, Van Sise M, Pradhan TS, Lee V, Pearl ML, Lee YC, Abulafia O. Hemoglobin A1c and the relationship to stage and grade of endometrial cancer. Arch Gynecol Obstet. 2012 Dec;286(6):1507-12.[PubMed]
3.McMeekin DS, Sill MW, Darcy KM, Abulafia O, Hanjani P, Pearl ML, Rubin SC, Rose PG, Small L, Benbrook DM. A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Nov;127(2):356-61.[PubMed]
4.Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, Barakat R, Pearl ML, Sharma SK. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol. 2012 Mar1;30(7):695-700. Erratum in: J Clin Oncol. 2012 May 1;30(13):1570.[PubMed][Full Text]
5.Hurteau JA, Brady MF, Darcy KM, McGuire WP, Edmonds P, Pearl ML, Ivanov I, Tewari KS, Mannel RS, Zanotti K, Benbrook DM. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol. 2010 Dec;119(3):444-50.[PubMed]
6.Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, Spiegel G, Barakat R, Pearl ML, Sharma SK. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol. 2009 Nov 10;27(32):5331-6.[PubMed[Full Text]
7.Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, Waggoner SE, Boardman CH. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol. 2009 Jun 1;27(16):2686-91.[PubMed][Full Text]
8.Fan T, Zhao Q, Chen JJ, Chen WT, Pearl ML. Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. Gynecol Oncol. 2009 Jan;112(1):185-91.[PubMed][Full Text]
9.Kavanagh JJ, Sill MW, Ramirez PT, Warshal D, Pearl ML, Morgan MA. Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Int J Gynecol Cancer. 2008 May-Jun;18(3):460-4.[PubMed]
10.Pearl ML, Johnston CM, McMeekin DS. A phase II study of weekly docetaxel for patients with advanced or recurrent cancer of the cervix. Gynecol Obstet Invest. 2007;64(4):193-8.[PubMed]

an image is here

See Dr. Pearl's Full Bibliography at the National Center for Biotechnology Information

Return to top ↑